Key result
High-dose IVIG rapidly improves platelet count in a patient with autoimmune HIT following TAVI.
Why the study?
Autoimmune heparin-induced thrombocytopenia after transcatheter aortic valve implantation is rare and its optimal treatment is not well established.
Case Report (n=1)
High-dose intravenous immunoglobulin may be an effective adjunct treatment for severe autoimmune heparin-induced thrombocytopenia following transcatheter aortic valve implantation.
Answers are grounded in this paper and cite their sources.
High-dose IVIG may merit consideration in refractory autoimmune HIT post-TAVI; case report leaves open need for controlled trials.
We describe a rare case of autoimmune heparin-induced thrombocytopenia after transcatheter aortic valve implantation in which antibodies against platelet factor 4/heparin have led to platelet activation even after heparin cessation, causing a delayed drop in platelet count to below 20 × 109/L. Most interestingly, platelet count rapidly improved after intravenous immunoglobulin treatment and no new thromboembolic complications were observed with further anticoagulation with rivaroxaban.
No takes yet. Share an insight, caveat, or question.
Bakchoul et al. (2019) conducted a case report in Autoimmune heparin-induced thrombocytopenia after transcatheter aortic valve implantation (n=1). High-Dose Intravenous Immunoglobulin was evaluated on Platelet count improvement. High-dose intravenous immunoglobulin rapidly improved platelet count in a patient with autoimmune heparin-induced thrombocytopenia after transcatheter aortic valve implantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: